Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Open Access
- 1 November 1995
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 182 (5), 1609-1614
- https://doi.org/10.1084/jem.182.5.1609
Abstract
The immune system can recognize differentiation antigens that are selectively expressed on malignant cells and their normal cell counterparts. However, it is uncertain whether immunity to differentiation antigens can effectively lead to tumor rejection. The mouse brown locus protein, gp75 or tyrosinase-related protein 1, is a melanocyte differentiation antigen expressed by melanomas and normal melanocytes. The gp75 antigen is recognized by autoantibodies and autoreactive T cells in persons with melanoma. To model autoimmunity against a melanocyte differentiation antigen, mouse antibodies against gp75 were passively transferred into tumor-bearing mice. Passive immunization with a mouse monoclonal antibody against gp75 induced protection and rejection of both subcutaneous tumors and lung metastases in syngeneic C57BL/6 mice, including established tumors. Passive immunity produced coat color alterations but only in regenerating hairs. This system provides a model for autoimmune vitiligo and shows that immune responses to melanocyte differentiation antigens can influence mouse coat color. Immune recognition of a melanocyte differentiation antigen can reject tumors, providing a basis for targeting tissue autoantigens expressed on cancer.Keywords
This publication has 29 references indexed in Scilit:
- Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cellsInternational Journal of Cancer, 1994
- A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1994
- Cancer antigens: immune recognition of self and altered self.The Journal of Experimental Medicine, 1994
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- Functional Properties of Cloned Melanogenic ProteinsPigment Cell Research, 1992
- Prolonged survival in metastatic malignant melanoma associated with vitiligoClinical and Experimental Dermatology, 1991
- Suppression of established pulmonary metastases by murine melanoma-specific monoclonal antibodiesInternational Journal of Cancer, 1991
- IFN-treatment of B16-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spreadClinical & Experimental Metastasis, 1988
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983
- Antibodies to normal human melanocytes in vitiligo.The Journal of Experimental Medicine, 1983